Madrigal Pharma Reports Positive Data from Phase 2 NASH Trials
Madrigal Pharmaceuticals (MDGL) reported new data from a Phase 2 clinical trial assessing resmetirom in patients suffering from nonalcoholic steatohepatitis ((NASH)) and fibrosis. The data demonstrated that once-a-day dosage of 80 mg or 100 mg of the drug candidate produced respectively 50 percent and above 60 percent reductions in liver fat per new analyses of Phase 2 data. The company also said that its Phase 3 trials MAESTRO-NASH and MAESTRO-NAFLD-1 will progress without any change in protocol.
The key findings from the trial showed that